# ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

> **NCT00132379** · PHASE1 · COMPLETED · sponsor: **Active Biotech AB** · enrollment: 13 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** ABR-217620
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00132379
- **Lead sponsor:** Active Biotech AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2014-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00132379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00132379, "ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00132379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*